SecBot SecBot
PRESS-RELEASE ·Filed May 29, 2026

SABS

SAB Biotherapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonmonths Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

This is a routine conference participation announcement with no new data. The next meaningful catalyst is the SAFEGUARD Phase 2b topline readout in 2H 2027. No trading action warranted based on this filing.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$3.60
T+0 close · May 29, 2026 · via day close
Latest settled
+0.56%
T+60 · $3.62
Vs SPY
−0.63%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 29 $3.60entry
  2. T+1 · 6mo ago −4.44%α −4.72% · $3.44
  3. T+5 · 6mo ago −6.67%α −6.37% · $3.36
  4. T+20 · 5mo ago +8.33%α +10.13% · $3.90
  5. T+60 · 3mo ago +0.56%α −0.63% · $3.62
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

SAB Biotherapeutics announced upcoming data presentations at the ADA and FOCIS conferences in June 2026, highlighting its lead program SAB-142 for type 1 diabetes. The press release contains no new clinical data, financial results, or regulatory milestones, it is a routine conference participation announcement with no material impact on the company's valuation.

Key Facts

  • SAB BIO will present an oral presentation at ADA 2026 (June 5-8) and a poster at FOCIS 2026 (June 9-12).
  • Presentations focus on SAB-142, a fully human anti-thymocyte immunoglobulin for Stage 3 type 1 diabetes.
  • Topline data readout for the registrational Phase 2b SAFEGUARD study expected in 2H 2027.
  • No new clinical data, financial figures, or regulatory decisions were disclosed in this press release.

Financial Impact

No financial impact, no new data, guidance, or material events disclosed.

Risk Factors

  • SAB-142 is still in clinical development with no approved product; regulatory and clinical trial risks remain.
  • Cash burn and financing risk for a clinical-stage biotech with no revenue.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3303527

Track record

15 reports on SABS

Performance horizon

3 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +15.67% at T+20 after the Oct 13, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $3.00 Now $3.00 0.00% settles Dec 15
  2. Nov 16, 2026today SC 13G/A Neutral 4/10 Entry $2.96 Now $3.00 +1.35% settles Dec 15
  3. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $3.00 Now $3.00 0.00% settles Dec 15
  4. Nov 5, 202611d ago Press Release Neutral 4/10 Entry $2.94 Now $3.00 +2.04% settles Dec 4
  5. Oct 22, 202625d ago 25-NSE Neutral 2/10 Entry $2.84 Now $3.00 +5.63% settles Nov 20
  6. Oct 13, 20264w ago 8-K Bullish 6/10 Entry $2.68 to $3.07 Now $3.00 +11.94% ▲ +14.55% +18.16% vs SPY
  7. Oct 13, 20264w ago Press Release Bullish 5/10 Entry $2.68 to $3.10 Now $3.00 +11.94% ▲ +15.67% +19.34% vs SPY
  8. Jul 7, 202618w ago 8-K Bullish 4/10 Entry $3.90 to $3.79 Now $3.00 −23.08% ▼ −2.82% −4.15% vs SPY
  9. May 29, 202624w ago Press Release Neutral 3/10 Viewing Entry $3.60 to $3.90 Now $3.00 −16.67% ▲ +8.33% +10.13% vs SPY
  10. May 12, 202626w ago Press Release Bearish 7/10 Entry $3.62 to $3.31 Now $3.00 +17.13% ▲ +8.56% +6.84% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 29, 2026